China Court Upholds Novo Nordisk's Semaglutide Patent, Defers Sales Impact
Event summary
- China’s Supreme People’s Court upheld the validity of Novo Nordisk’s semaglutide compound patent, affirming a previous Beijing IP Court ruling.
- The ruling concerns semaglutide, the active ingredient in Novo Nordisk’s Wegovy (obesity), Ozempic (diabetes), and Rybelsus (diabetes).
- Novo Nordisk estimates a low-single-digit negative impact on global sales growth in 2026 due to patent expiry in other countries, a forecast unchanged by this ruling.
- Semaglutide has accumulated approximately 38 million patient-years of use since its launch.
The big picture
This ruling provides a degree of protection for Novo Nordisk’s blockbuster semaglutide franchise in China, a critical market for the company’s growth. While the company has already accounted for patent expiry elsewhere, the Chinese market represents a significant portion of potential future revenue. The decision underscores the increasing importance of intellectual property protection in China for foreign pharmaceutical companies, and signals a willingness by the Chinese government to uphold such protections, albeit with the understanding that eventual generic competition is inevitable.
What we're watching
- Market Response
- The market’s reaction to this ruling will likely be muted, as the impact on Novo Nordisk’s overall revenue is already factored in, but any unexpected shifts in investor sentiment should be noted.
- Generic Competition
- The pace at which generic manufacturers in China attempt to circumvent or challenge the patent, despite this ruling, will be a key indicator of future competitive pressure.
- Geographic Scope
- How this decision influences Novo Nordisk’s patent strategy and enforcement efforts in other international markets facing similar patent expiry timelines warrants observation.
Related topics